An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 57, Issue 10, 2018, Pages 1707-1720

  Teng, Y K Onno ^a   Bredewold, Edwin O W ^a   Rabelink, Ton J ^a   Huizinga, Tom W J ^a   Eikenboom, H C Jeroen ^a   Limper, Maarten ^b   Fritsch Stork, Ruth D E ^b,c,d   Bloemenkamp, Kitty W M ^e   Sueters, Marieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Hanusch Hospital   (Netherlands)

^d SIGMUND FREUD UNIVERSITY   (Austria)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

anti phospholipid syndrome; counselling; glomerulonephritis; lupus nephritis; neonatal lupus; preconception counselling; pregnancy; systemic lupus erythematosus

Indexed keywords

ADVERSE OUTCOME; ANTIPHOSPHOLIPID SYNDROME; COHORT ANALYSIS; CONGENITAL HEART BLOCK; COUNSELING; EVIDENCE BASED PRACTICE; FEMALE; FETUS CIRCULATION; FETUS DISEASE; HIGH RISK PREGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS; PATIENT MONITORING; PLACENTA DISORDER; PRE PREGNANCY COUNSELLING; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; COMPLICATION; FAMILY PLANNING; NEWBORN; PREGNANCY; PREPREGNANCY CARE; PROCEDURES; PSYCHOLOGY; YOUNG ADULT;

ADULT; COUNSELING; FAMILY PLANNING SERVICES; FEMALE; HUMANS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; YOUNG ADULT;

EID: 85053128096     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex374     Document Type: Review

References (99)

1. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001;357:1027-32
2. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27
3. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:c2541
4. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199:127
5. Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85
6. Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205
7. Andreoli L, Bazzani C, Taraborelli M et al. Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 2010;10:51-4
8. Moroni G, Doria A, Giglio E et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 2016;74:6-12
9. Arkema EV, Palmsten K, Sjowall C et al. What to expect when expecting with systemic lupus erythematosus (SLE): a population-based study of maternal and fetal outcomes in SLE and pre-SLE. Arthritis Care Res 2016;68:988-94
10. Buyon JP, Kim MY, Guerra MM et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 2015;163:153-63
11. Smyth A, Oliveira GH, Lahr BD et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060-8
12. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82
13. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21
14. Gladman DD, Tandon A, Ibanez D, Urowitz MB. The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications. J Rheumatol 2010;37:754-8
15. Ko HS, Ahn HY, Jang DG et al. Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci 2011;8:577-83
16. Hou SH, Grossman SD, Madias NE. Pregnancy in women with renal disease and moderate renal insufficiency. Am J Med 1985;78:185-94
17. Zhang JJ, Ma XX, Hao L et al. A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol 2015;10:1964-78
18. Piccoli GB, Attini R, Vasario E et al. Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol 2010;5:844-55
19. Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of preeclampsia and related podocyte injury. Kidney Int 2014;86:275-85
20. White WM, Garrett AT, Craici IM et al. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury. PLoS One 2014;9:e92693
21. Fakhouri F, Vercel C, Fremeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012;7:2100-6
22. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 125: Chronic hypertension in pregnancy. Obstetrics Gynecol 2012;119(2 Pt 1):396-407
23. Walker JJ. Pre eclampsia. Lancet 2000;356:1260-5
24. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565
25. Henderson JT, Whitlock EP, O'Connor E et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160:695-703
26. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation 2006;114:1873-82
27. Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 2015;24:131-8
28. MacDorman MF, Gregory EC. Fetal and perinatal mortality: United States, 2013. Natl Vital Stat Rep 2015;64:1-24
29. WHO World Health Statistics. 2016, http://apps.who. int/gho/data/view.sdg.3-2-data-reg?lang=en (July 2017, date last accessed)
30. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003;142:678-83
31. Eronen M, Siren MK, Ekblad H et al. Short-and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000;106(1 Pt 1):86-91
32. Izmirly PM, Saxena A, Kim MY et al. Maternal and fetal factors associated with mortality and morbidity in a multiracial/ ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011;124:1927-35
33. Jaeggi ET, Fouron JC, Silverman ED et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004;110:1542-8
34. Levesque K, Morel N, Maltret A et al. Description of 214 cases of autoimmune congenital heart block: results of the French neonatal lupus syndrome. Autoimmun Rev 2015;14:1154-60
35. Lopes LM, Tavares GM, Damiano AP et al. Perinatal outcome of fetal atrioventricular block: one-hundred-sixteen cases from a single institution. Circulation 2008;118:1268-75
36. Skog A, Lagnefeldt L. Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block. Acta Obstet Gynecol Scand 2016;95:98-105
37. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76-82
38. Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12. additional sets. Am J Med 1975;59:533-52
39. Deapen D, Escalante A, Weinrib L et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311-8
40. Somers EC, Antonsen S, Pedersen L, Sorensen HT. Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter? Ann Rheum Dis 2013;72:525-9
41. Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 2016;55:1693-7
42. Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice. Rheumatology 2016;55:1698-702
43. Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810
44. Belimumab Pregnancy Registry. https://clinicaltrials. gov/ct2/show/NCT01532310?term=belimumab+pregnancy&rank=1 (July 2017, date last accessed)
45. Burnett AE, Mahan CE, Vazquez SR et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41:206-32
46. Konigsbrugge O, Langer M, Hayde M, Ay C, Pabinger I. Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost 2014;112:1323-4
47. Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol 2016;105:117-26
48. Myers B, Neal R, Myers O, Ruparelia M. Unplanned pregnancy on a direct oral anticoagulant (rivaroxaban): a warning. Obstet Med 2016;9:40-2
49. Wiesen MH, Blaich C, Muller C et al. The direct factor Xa inhibitor rivaroxaban passes in to human breast milk. Chest 2016;150:e1-4
50. Bapat P, Pinto LS, Lubetsky A et al. Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost 2016;14:1436-41
51. Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 2015;213:710.e1-6
52. Kidney Disease: Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150
53. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
54. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51
55. Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997;350:1446-7
56. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 1992;80(3 Pt 1):429-32
57. Tabacova SA, Kimmel CA. Enalapril: pharmacokinetic/ dynamic inferences for comparative developmental toxicity. A review. Reprod Toxicol 2001;15:467-78
58. Velazquez-Armenta EY, Han JY, Choi JS, Yang KM, Nava-Ocampo AA. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 2007;26:51-66
59. Visintin C, Mugglestone MA, Almerie MQ et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010;341:c2207
60. Weber-Schoendorfer C, Chambers C, Wacker E et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 2014;66:1101-10
61. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology 2014;53:757-63
62. Teruel C, Lopez-Roman A, Bermejo F et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010;105:2003-8
63. Zink A, Vencovsky J, Cutolo M et al. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Ann Rheum Dis 2015;67:296-301
64. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157:47-58
65. Zink A, Vencovsky J, Cutolo M et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Ann Rheum Dis 2006;4:295-306
66. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;2:CD002859
67. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996;35:402-7
68. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7
69. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13
70. Laskin CA, Spitzer KA, Clark CA et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009;36:279-87
71. Zhang T, Ye X, Zhu T et al. Antithrombotic treatment for recurrent miscarriage: Bayesian network meta-analysis and systematic review. Medicine 2015;94:e1732
72. National Collaborating Centre for Women and Children's Health (UK). Ectopic pregnancy and miscarriage: diagnosis and initial management. London: National Institute for Health and Clinical Excellence, 2012
73. Mehndiratta S, Suneja A, Gupta B, Bhatt S. Fetotoxicity of warfarin anticoagulation. Arch Gynecol Obstet 2010;282:335-7
74. Derksen RH, Groot PG, Nieuwenhuis HK, Christiaens GC. How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis 2001; 60:1-3
75. Royal College of Obstetricians and Gynaecologists. Thrombosis and Embolism During Pregnancy and the Puerperium. Green-top Guideline No. 37a. London: Royal College of Obstetricians and Gynaecologists, 2015
76. Leroux M, Desveaux C, Parcevaux M et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015;24:1384-91
77. Sciascia S, Hunt BJ, Talavera-Garcia E et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016;214:273.e1-8
78. Levy RA, Vilela VS, Cataldo MJ et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebocontrolled study. Lupus 2001;10:401-4
79. Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res. Clin Rheumatol 2006;20:685-94
80. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974
81. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohort study. BMJ 2001;323:1213-7
82. Nili F, McLeod L, O'Connell C, Sutton E, McMillan D. Maternal and neonatal outcomes in pregnancies complicated by systemic lupus erythematosus: a populationbased study. J Obstet Gynaecol 2013;35:323-8
83. Cavallasca JA, Laborde HA, Ruda-Vega H, Nasswetter GG. Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE). Clin Rheumatol 2008;27:41-6
84. Carvalheiras G, Vita P, Marta S et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin Rev Allergy Immunol 2010;38:302-6
85. Jakobsen IM, Helmig RB, Stengaard-Pedersen K. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990-2010. Scandinavian J Rheumatol 2015;44:377-84
86. Park EJ, Jung H, Hwang J, et al. Pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective review of 62 pregnancies at a single tertiary center in South Korea. Int J Rheumatic Dis 2014;17:887-97
87. Koh JH, Ko HS, Lee J et al. Pregnancy and patients with preexisting lupus nephritis: 15 years of experience at a single center in Korea. Lupus 2015;24:764-72
88. Chen CY, Chen YH, Lin HC, Chen SF, Lin HC. Increased risk of adverse pregnancy outcomes for hospitalisation of women with lupus during pregnancy: a nationwide population-based study. Clin Experimental Rheumatol 2010;28:49-55
89. Ku M, Guo S, Shang W et al. Pregnancy Outcomes in Chinese Patients with Systemic Lupus Erythematosus (SLE): A Retrospective Study of 109 Pregnancies. PloS One 2016;11(7):e0159364
90. Yang H, Liu H, Xu D et al. Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flaresa case control study. PloS One 2014;9(8):e104375
91. Lv J, Wang W, Li Y. Clinical outcomes and predictors of fetal and maternal consequences of pregnancy in lupus nephritis patients. Int Urol Nephrol 2015;47:1379-85
92. Liu J, Zhao Y, Song Y et al. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. J Maternal-Fetal Neonatal Med 2012;25:261-6
93. Chen S, Sun X, Wu B, Lian X. Pregnancy in Women with Systemic Lupus Erythematosus: A Retrospective Study of 83. Pregnancies at a Single Centre. Int J Environmental Res Public Health 2015;12:9876-88
94. Teh CL, Wan SA, Cheong YK, Ling GR. Systemic lupus erythematosus pregnancies: ten-year data from a single centre in Malaysia. Lupus 2016
95. Teh CL, Wong JS, Ngeh NK, Loh WL. Systemic lupus erythematosus pregnancies: the Sarawak experience and review of lupus pregnancies in Asia. Rheumatol Int 2011;31:1153-7
96. Ideguchi H, Ohno S, Uehara T, Ishigatsubo Y. Pregnancy outcomes in Japanese patients with SLE: retrospective review of 55 pregnancies at a university hospital. Clin Rev Allergy Immunol 2013;44:57-64
97. Madazli R, Yuksel MA, Oncul M, Imamoglu M, Yilmaz H. Obstetric outcomes and prognostic factors of lupus pregnancies. Arch Gynecol Obstet 2014;289:49-53
98. Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus 2010;19:1665-73
99. Taylor J. The first ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011;32:3055-6